The latest announcement is out from Kamada ( (IL:KMDA) ).
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Kamada Ltd. has announced its financial guidance for 2024 and 2025, projecting continued double-digit profitable growth. In 2025, the company expects revenues of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million, marking a significant increase from 2024 figures. Kamada plans to enhance its business through strategic growth pillars, including expanding plasma collection operations and advancing its pivotal Phase 3 Inhaled AAT program. The company’s robust financial performance positions it for significant business development and M&A transactions, which are expected to further enrich its product portfolio and strengthen its market presence.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived products for rare and serious conditions. The company has a diverse commercial portfolio, including six FDA-approved plasma-derived biopharmaceutical products, and is also focused on the research and development of new product candidates. Kamada operates in over 30 countries, leveraging its expertise in plasma-derived and biopharmaceutical fields, and is supported by FIMI Opportunity Funds, its controlling shareholder.
YTD Price Performance: 7.42%
Average Trading Volume: 39,260
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $378.4M
For a thorough assessment of KMDA stock, go to TipRanks’ Stock Analysis page.
